Structuring the Added Value of Biomedicine Products in the Innovative Economy

  • Natalia G. VaraksaEmail author
  • Sergey A. Alimov
  • Maria S. Alimova
  • Victor A. Konstantinov
Conference paper
Part of the Lecture Notes in Networks and Systems book series (LNNS, volume 91)


In modern conditions, biomedicine, as a priority sector of the innovation economy, is developing dynamically, due to the desire of the world community to increase the quality of life, duration, financial security, and social well-being. The basis of the structuring of biomedical products is a step-by-step process of transformation of the scientific idea and innovative project into the final product of the industry, having a value assessment and high practical relevance to all stakeholders. One of the criteria of success of an innovative product is the indicator of added value. The aim of the research is to determine the multi-element composition of added value of innovative products in biomedicine and develop its gradual structuring on the basis of a generalization of modern domestic and world level research. The article analyzes the specific structure of biomedicine products, reveals the essence of added value as an indicator integrating assessment and analytical procedures that determine the importance and relevance of a particular biomedical product for the population, government, business community, as well as the degree of need for its early development, approbation, and implementation. A step-by-step structuring of the value added of biomedicine products has been developed and its element-wise composition has been evaluated. Practical significance of which lies in the possibility of making alternative choices at the government level for investment purposes and at the business community level in order to introduce the most promising option from the point of view of mass production and obtaining the maximum socio-economic and financial effect.


Innovative product Value added Innovations Biomedicine Economy 

JEL Code

D24 L65 


  1. Petty, V., Smith, A., Ricardo, D.: Anthology of economic classics, 199 p. (1993)Google Scholar
  2. Alimova, M.S.: Essence and elemental structure of added value. Polythematic Netw. Electron. Sci. J. Kuban State Agrarian Univ. 100, 1423–1433 (2014)Google Scholar
  3. Vasilyev, A.N.: Qualitative preclinical research - the necessary stage of development and introduction into clinical practice of new drugs. Antibiot. Chemother. 57, 41–46 (2012)Google Scholar
  4. Dedkova, E.G.: Communication interaction of elements in the information system of assessment, accounting, analysis and control of cost flows. Manag. Acc. 10, 52–57 (2017)Google Scholar
  5. Krutikov, V.E., Kostina, O.I., Shakhmetova, E.A.: Innovations in the development of the region: cluster of pharmaceuticals, biomedicine and biotechnologies. Bull. Bryansk State Univ. 3, 25–32 (2013)Google Scholar
  6. Marx, K., Engels, F.: Capital. Criticism of political economy. Volume one, 2nd edn., vol. 23, 632 p. (1960)Google Scholar
  7. Malkina, E.L.: Conceptual bases of the theory of cost flows in the framework of the modern understanding of the category “cost”. Manage. Econ. Syst. 10, 25–36 (2016)Google Scholar
  8. Maslov, B.G.: Construction of a model of management accounting of formation of value in the conditions of integrated data processing. Econ. Hum. Sci. 6/212(580), 28–34 (2009)Google Scholar
  9. Maslova, I.A.: The methodology of formation of branch added value and value of products in fair valuation. Manage. Acc. 4, 92–99.4 (2012)Google Scholar
  10. Pankrushina, A.N., Dementieva, S.M., Ivanova, S.A.: The role of biotechnology in the formation of knowledge-based economy. Fundam. Res. 6, 26–35 (2017)Google Scholar
  11. Peshina, E.V., Avdeev, P.A.: Formation of gross added value of high-tech and knowledge-intensive products (goods, services). News UrGEU 6(50), 46–56 (2013)Google Scholar
  12. Starodubov, V.I., Kurakova, N.G.: Financing of medical science: new principles and financial instruments. Health Manager 3, 48–60 (2014)Google Scholar
  13. Honle, T.A.: Expenses for development of innovative drug. Problems of accounting and finance, no. 2(10) (2013).
  14. Garina, E.P., Kuznetsova, S.N., Garin, A.P., Romanovskaya, E.V., Andryashina, N.S., Suchodoeva, L.F.: Increasing productivity of complex product of mechanic engineering using modern quality management methods. Acad. Strateg. Manage. J. 16(4), 8 p. (2017)Google Scholar
  15. Frost & Sullivan Review of the market of biotechnology in Russia and assessment of prospects of its development (2014).
  16. Potashnik, Y.S., Garina, E.P., Romanovskaya, E.V., Garin, A.P., Tsymbalov, S.D.: Determining the value of own investment capital of industrial enterprises. Adv. Intell. Syst. Comput. 622, 170–178 (2018)Google Scholar
  17. Yashin, S.N., Trifonov, Y.V., Koshelev, E.V., Garina, E.P., Kuznetsov, V.P.: Evaluation of the effect from organizational innovations of a company with the use of differential cash flow. Adv. Intell. Syst. Comput. 622, 208–216 (2018). Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Natalia G. Varaksa
    • 1
    Email author
  • Sergey A. Alimov
    • 1
  • Maria S. Alimova
    • 1
  • Victor A. Konstantinov
    • 1
  1. 1.Orel State University named after I.S. TurgenevOrelRussia

Personalised recommendations